1. Bener A, Dafeeah EE, Abou-Saleh MT, Bhugra D, Ventriglio A. Schizophrenia and co-morbid obsessive - compulsive disorder: Clinical characteristics. Asian J Psychiatr 2018; 37: 80-84.
2.
Bobes J, Arango C, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry 2010; 71(3): 280-286.
3.
De Berardis D, Vellante F, Fornaro M, Orsolini L, Valchera A, Baroni G et al. Rapid improvement of obsessive-compulsive disorder associated with schizophrenia with cariprazine add-on in a subject under paliperidone long-acting injection: a case report.Int Clin Psychopharmacol 2020; 35(2): 113-118.
4.
Grillault Laroche D, Gaillard A. Induced Obsessive Compulsive Symptoms (OCS) in schizophrenia patients under Atypical 2 Antipsychotics (AAPs): review and hypotheses. Psychiatry Res. 2016; 30; 246: 119-128.
5.
Kokurcan A, Nazlı ŞB. Clinical correlates of obsessive-compulsive disorder comorbidity in patients with schizophrenia. Indian J Psychiatry 2020; 62(1): 51-58.
6.
Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 2018; 268(7): 625-639.
7.
Leucht S, Komossa K, Rummel-Kluge Ch, Corves C, Hunger H, Schmid F et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009 Feb; 166(2): 152-63.
8.
Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A. Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(3): 333-346.
9.
Misiak B, Bieńkowski P, Samochowiec J. Cariprazine – a novel antipsychotic drug and its place in the treatment of schizophrenia. Kariprazyna – nowy lek przeciwpsychotyczny i jego miejsce w leczeniu schizofrenii. Psychiatr Pol 2018; 52(6): 971‐981.
10.
Neill JC, Grayson B, Kiss B, Gyertyán I, Ferguson P, Adham N. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur Neuropsychopharmacol 2016; 26(1): 3‐14.
11.
Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017; 389(10074): 1103-1113.
12.
Poyurovsky M, Weizman A, Weizman R. Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs 2004; 18: 989-1010.
13.
Schirmbeck F, Zink M. Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors. Front Pharmacol 2013; 4: 99.
14.
Szulc A, Dudek D, Samochowiec J, Wojna M, Heitzman J, Gałecki P. Rekomendacje dotyczące leczenia schizofrenii z objawami negatywnymi. Standardy farmakoterapii Polskiego Towarzystwa Psychiatrycznego, część 2. Psychiatr Pol 2019; 53(3): 525-540.
15.
Szulc A, Samochowiec J. Schizofrenia z objawami negatywnymi. PZWL Wydawnictwo Lekarskie, Warszawa 2019.
16.
Tezenas du Montcel C, Pelissolo A, Schürhoff F, Pignon B. Obsessive-Compulsive Symptoms in Schizophrenia: an Up-To-Date Review of Literature. Curr Psychiatry Rep 2019; 21(8): 64.
17.
Vázquez-Bourgon J, Rodríguez-Rodríguez P, Gómez-Ruíz E, Artal J, Crespo-Facorro B. Obsessive-compulsive symptoms induced by long-acting injectable paliperidone in a patient with schizophrenia: a case report. Ann Clin Psychiatry 2014; 26(4): 301-302.